^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MBF-362

    i
    Other names: MBF-362
    Associations

    News

    Trials
    Company:
    Medibiofarma
    Drug class:
    PGE4 antagonist
    Related drugs:
    Associations

    News

    Trials
    9ms
    First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors (clinicaltrials.gov)
    P1, N=16, Completed, Medibiofarma S.L. | Recruiting --> Completed | N=41 --> 16
    Trial completion • Enrollment change
    |
    MBF-362
    1year
    First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors (clinicaltrials.gov)
    P1, N=41, Recruiting, Medibiofarma S.L. | Trial primary completion date: Oct 2024 --> Jan 2025
    Trial primary completion date
    |
    MBF-362
    over1year
    First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors (clinicaltrials.gov)
    P1, N=41, Recruiting, Medibiofarma S.L. | Trial primary completion date: May 2024 --> Oct 2024
    Trial primary completion date
    |
    MBF-362
    over2years
    First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors (clinicaltrials.gov)
    P1, N=41, Recruiting, Medibiofarma S.L.
    New P1 trial
    |
    MBF-362